The STORM trial presented at ESTRO24 – APCCC

Advanced Prostate Cancer Consensus Conference (APCCC) shared on X:

“The STORM trial presented at ESTRO24:

Evaluated treatment strategies for pelvic nodal oligo-recurrence in prostate cancer patients after radical treatment.

This phase II trial involved 196 patients and compared elective nodal radiotherapy (ENRT) to stereotactic body radiation therapy (SBRT) targeting only visible nodes, with both groups receiving six months of androgen deprivation therapy (ADT).

Results showed that ENRT significantly improved biochemical relapse-free survival (69% vs. 47%) and locoregional relapse-free survival (90% vs. 70%) compared to SBRT. Although toxicity rates were similar, persistent genitourinary toxicity was more frequent in the ENRT group.

ENRT was recommended as the optimal treatment to maximize survival outcomes in these patients.”

Source: APCCC/X